Karriereverlauf von Lisa M. Bell
Ehemalige bekannte Positionen von Lisa M. Bell
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| COHERUS BIOSCIENCES, INC. | General Counsel | 12.05.2014 | 01.12.2017 |
Abbott Biotherapeutics Corp.
 Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | General Counsel | - | - |
| BIOMARIN PHARMACEUTICAL INC. | General Counsel | - | - |
Ausbildung von Lisa M. Bell
| University of California, Berkeley | Doctorate Degree |
| Boston University | Graduate Degree |
Statistik
International
| Vereinigte Staaten | 6 |
Operativ
| General Counsel | 3 |
| Doctorate Degree | 1 |
| Graduate Degree | 1 |
Sektoral
| Health Technology | 4 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| COHERUS BIOSCIENCES, INC. | Health Technology |
| BIOMARIN PHARMACEUTICAL INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | Health Technology |
- Börse
- Insiders
- Lisa M. Bell
- Erfahrung
